Retatrutide — 20mg

Retatrutide 20mg is the largest single-vial format of this triple GLP-1/GIP/glucagon receptor agonist, designed for research environments running high-volume protocols, longitudinal cohort studies, or multi-arm comparative designs. For labs tracking the full 68-week trajectory mirrored in Phase 3 TRIUMPH-4 data, the 20mg presentation reduces logistical burden and ensures supply continuity across the entire study window.

The compound's tri-agonist mechanism — simultaneously addressing caloric intake (GLP-1R), insulin sensitivity (GIPR), and direct hepatic fat mobilization (GCGR) — makes it the most mechanistically complete metabolic peptide in clinical development. This pharmacological completeness is precisely why its clinical outcomes have exceeded all predecessor agents. Researchers interested in disentangling the individual receptor contributions to the observed 28.7% Phase 3 weight loss outcome will find this format provides the quantity needed for receptor-specific inhibition experiments using selective antagonists.

Beyond weight research, the 20mg vial is well-suited to the growing body of work on retatrutide's weight-independent effects — particularly its anti-inflammatory activity in synovial tissue (relevant to knee osteoarthritis trials) and its hepatoprotective effects in NASH models, where glucagon receptor activation reduces hepatic steatosis through mechanisms distinct from caloric restriction.